Evaxion Biotech A/S announced on February 25, 2025, an extension of its ongoing Phase 2 trial for EVX-01, its personalized cancer vaccine, from two to three years. This extension aims to further enhance the clinical data package for EVX-01, which is being developed for advanced melanoma.
Active participants in the trial will be offered the opportunity to enter the one-year extension phase after completing the initial two-year protocol. During this extension, patients will receive additional EVX-01 doses as monotherapy, allowing for assessment of clinical response duration and immune activation.
The trial extension involves minimal additional costs, as trial sites are already operational. Two-year data readout for EVX-01 is still expected in the second half of 2025, with the additional year providing a more comprehensive understanding of the treatment's long-term effects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.